Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
This statement is based on a regulatory approval from the Health Canada:
PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.